Prevalence of autoantibodies against 3-DG-glycated H2A protein in type 2 diabetes


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Advanced glycation end-products (AGEs) have been found to be critically involved in initiation or progression of diabetes secondary complications (nephropathy, retinopathy, neuropathy, and angiopathy). Various hyper-glycating carbonyl compounds such as 3-deoxyglucosone (3-DG) are produced in pathophysiological conditions that form AGEs in high quantity both in vivo and in vitro. In the first stage of this study, we glycated histone H2A protein by 3-DG, and the results showed the formation of various intermediates and AGEs as well as structural changes in the protein. In the second stage, we studied the immunogenicity of native and 3-DG-glycated H2A protein in female rabbits. The modified H2A was highly immunogenic, eliciting high titer immunogen-specific antibodies, while the unmodified form was almost nonimmunogenic. Antibodies against standard carboxymethyllysine (CML) and pentosidine were detected in the immunized female rabbits, which demonstrates the immunogenic nature of AGEs (CML and pentosidine) as well. The results show both structural perturbation and AGEs have the capacity of triggering the immune system due to the generation of neoepitopes that render the molecule immunogenic. This study shows the presence of autoantibodies against 3-DG-modified H2A, CML, and pentosidine in the sera of type 2 diabetes patients having secondary complications. Autoantibodies against damaged H2A and AGEs may be significant in the assessment of initiation/progression of secondary complications in type 2 diabetes mellitus patients or may be used as a marker for early detection of secondary complications in diabetes.

Sobre autores

J. Ashraf

Faculty of Applied Medical Sciences

Autor responsável pela correspondência
Email: jmashraf@gmail.com
Arábia Saudita, Jazan

S. Abdullah

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Arábia Saudita, Jazan

S. Ahmad

Department of Biotechnology

Email: jmashraf@gmail.com
Índia, Lucknow

S. Fatma

Faculty of Science

Email: jmashraf@gmail.com
Índia, Varanasi

M. Baig

Department of Medical Biotechnology

Email: jmashraf@gmail.com
República da Coreia, Gyeongsan

J. Iqbal

Faculty of Medicine

Email: jmashraf@gmail.com
Arábia Saudita, Jazan

A. Madkhali

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Arábia Saudita, Jazan

A. Jerah

Faculty of Applied Medical Sciences

Email: jmashraf@gmail.com
Arábia Saudita, Jazan


Declaração de direitos autorais © Pleiades Publishing, Ltd., 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies